NEW YORK CITY, NY / ACCESSWIRE / November 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
Investigation Details
On November 25, 2024, Cassava issued a press release announcing that its drug simufilam had failed to meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints in a Phase 3 study evaluating simufilam 100 mg tablets versus placebo over 52 weeks for the treatment of mild-to-moderate Alzheimer's disease ("AD"). In light of these disappointing results, Cassava also announced that it was discontinuing a second Phase 3 trial of simufilam 100 mg and 50 mg tablets versus placebo over 76 weeks for the treatment of mild-to-moderate AD. On this news, Cassava's stock price fell sharply during intraday trading on November 25, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Cassava securities, you can assist this investigation by visiting the firm's site: bgandg.com/SAVA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC